The Janssen Pharmaceutical Companies, a subsidiary of Johnson & Johnson, announced the US Food and Drug Administration’s approval of its first bispecific T-cell engager antibody, TECVAYLI (teclistamab-cqyv). The medication is intended for the treatment of relapsed or refractory multiple myeloma patients. TECVAYLI is indicated for patients previously treated with a proteasome inhibitor, immunomodulatory drug, and […]
Ayala Pharmaceuticals has been granted fast track designation for its oral gamma-secretase inhibitor AL102 by the US Food and Drug Administration (FDA) for the treatment of progressing desmoid tumors. AL102 is currently being assessed by the clinical-stage oncology company in the phase 2/3 RINGSIDE clinical trial in desmoid tumors. According to Ayala Pharmaceuticals, in Part […]
Enhertu FDA approval : AstraZeneca and Daiichi Sankyo have secured approval for Enhertu (trastuzumab deruxtecan) from the US Food and Drug Administration for the treatment of a type of metastatic breast cancer in adult patients. Enhertu is said to be a specifically engineered HER2-directed antibody drug conjugate (ADC). It is being co-developed and commercialized by […]
BriaCell Therapeutics has signed an exclusive licensing deal with the University of Maryland, Baltimore County (UMBC) to develop and commercialize Soluble CD80 (sCD80) as a biologic agent for cancer treatment. sCD80 was developed originally by Suzanne Ostrand-Rosenberg from the Emeritus Faculty at UMBC. According to BriaCell Therapeutics, sCD80 was well-tolerated in animal models, and by […]
Lantern Pharma has secured orphan drug designation for its small molecule drug candidate LP-184 from the US Food and Drug Administration (FDA) for the treatment of pancreatic cancer. According to the Texas-based clinical stage biopharma company, LP-184 is a next generation alkylating agent that selectively damages DNA in cancer cells that over-express certain biomarkers or […]
NeoGenomics, a US-based cancer diagnostics and pharma services company, has wrapped up its previously announced $390 million takeover of Inivata, a liquid biopsy platform company based in Cambridge, England. The deal was announced in May 2021 by NeoGenomics as it exercised a purchase option to acquire the remaining equity interest in Inivata. A year prior […]
Ambrx has announced that its antibody drug conjugate (ADC) ARX788 has been granted orphan drug designation by the US Food and Drug Administration for the treatment of patients having HER2-positive gastric cancer. The orphan drug designation for ARX788, announced in March 2021, for gastric cancer gives Ambrx with benefits such as inclusion of an exemption […]
Alkem Laboratories and Tata Memorial Centre (TMC) have joined to set up an advanced radiotherapy facility in Muzaffarpur, Bihar as a part of the Homi Bhabha Cancer Hospital and Research Center (HBCHRC). As part of its CSR activity, Alkem Laboratories has approved the purchase of two advanced versions of the teletherapy and brachytherapy units for […]
In a significant development for cancer treatment, Targovax, a Norwegian biotech firm specializing in immune-oncology, has announced that its lead candidate, ONCOS-102, has been granted Fast Track designation by the US Food and Drug Administration (FDA) for the treatment of malignant pleural mesothelioma, a rare and aggressive cancer. FDA’s Recognition Enhances Clinical Development The FDA’s […]
Siemens Healthineers acquisition of Varian Medical Systems : Germany-based Siemens Healthineers has signed an all-cash deal worth around $16.4 billion to acquire US-based cancer care technologies developer Varian Medical Systems with an objective to strengthen its oncology portfolio and bolster its position in the healthcare sector. Based in California, Varian Medical Systems is among the […]